Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Analysts Remain Bullish on Novavax; Promising Spike Projected

Stock Markets Aug 17, 2021 04:31AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Analysts Remain Bullish on Novavax; Promising Spike Projected

Novavax , Inc. (NASDAQ:NVAX) has helped many people live healthier lives by developing vaccines and other treatments. The company has been working for more than a decade to improve public health around the world. 

Novavax has tackled COVID-19, seasonal influenza, Ebola virus disease (EVD), Middle East Respiratory Syndrome Coronavirus (MERS), and Severe Acute Respiratory Syndrome (SARS).

Boasting cutting-edge vaccine technology, Novavax’s recombinant nanoparticle vaccines combine genetic engineering with traditional approaches. These solutions are customized against different pathogens that threaten human health. (See Novavax stock charts on TipRanks)

In the U.K. Phase 3 clinical trial of NVX-CoV2373 by Novavax, 96% of volunteers were protected against the original strain of COVID-19. The trial also showed 86% protection against the B1.1.7 (Alpha) variant strain, even among those aged 65 or older. This is important because the elderly are a high-risk group; impacted the most by disease complications from variants.

Valuation

Despite Novavax enjoying strong growth momentum and using cutting-edge technology to drive its vaccine innovation, the market is valuing the company quite reasonably. For example, it is only priced at 4.7x forward revenues, 11.6x forward earnings, and 21.6x forward free cash flow.

Revenues are expected to soar by 317% in 2021, and by another 177% in 2022. Earnings per share are expected to grow by 8.6% in 2021, and 515% in 2022.

Wall Street’s Take

From Wall Street analysts, Novavax earns a Strong Buy consensus rating based on 4 Buy recommendations in the past three months. Additionally, the average NVAX price target of $276.50 puts the upside potential at 20.6%.

Summary and Conclusions

Novavax is enjoying rapid revenue growth thanks to its innovative approach to vaccine development.

Furthermore, Wall Street analysts are overwhelmingly bullish on the stock. The current valuation looks very attractive relative to its growth prospects and competitive advantages. As a result, the stock looks like it could be a good buy at current levels.

Disclosure: On the date of publication, Samuel Smith had no position in any of the companies discussed in this article.

Disclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities.

Analysts Remain Bullish on Novavax; Promising Spike Projected
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email